Last reviewed · How we verify

Autologous Serum 50% — Competitive Intelligence Brief

Autologous Serum 50% (Autologous Serum 50%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous biological preparation. Area: Ophthalmology.

phase 3 Autologous biological preparation Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Autologous Serum 50% (Autologous Serum 50%) — Pontificia Universidad Catolica de Chile. Autologous serum 50% is a patient's own blood serum diluted to 50% concentration, applied topically to provide growth factors and immunomodulatory components for tissue repair and healing.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Autologous Serum 50% TARGET Autologous Serum 50% Pontificia Universidad Catolica de Chile phase 3 Autologous biological preparation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous biological preparation class)

  1. Pontificia Universidad Catolica de Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous Serum 50% — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-serum-50. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: